CN112578125B - Application of reagent for detecting content of calprotectin in preparation of ovarian lesion screening kit - Google Patents
Application of reagent for detecting content of calprotectin in preparation of ovarian lesion screening kit Download PDFInfo
- Publication number
- CN112578125B CN112578125B CN202011038492.5A CN202011038492A CN112578125B CN 112578125 B CN112578125 B CN 112578125B CN 202011038492 A CN202011038492 A CN 202011038492A CN 112578125 B CN112578125 B CN 112578125B
- Authority
- CN
- China
- Prior art keywords
- ovarian
- calprotectin
- reagent
- detection
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4727—Calcium binding proteins, e.g. calmodulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides application of a reagent for detecting the content of calprotectin (calprotectin) in excrement in preparing an ovarian lesion screening kit, belonging to the field of disease detection kits. According to the invention, the correlation between the content and ovarian lesion is obvious through detecting the content of the calprotectin in different groups of people, and the kit developed by the principle can be used for quickly and non-invasively screening the ovarian lesion, so that the application prospect is good.
Description
Technical Field
The invention belongs to the field of disease screening kits.
Background
Calprotectin was first isolated from neutrophils by Fagerhol in 1980 and named L1 protein, since it was found to contain calcium in its structure and to have antimicrobial properties, which has been known for 39 years today. Wilkinson et al, also named calgranulin in accordance with this antigenic characteristic in 1988, further demonstrated that these proteins have the structural characteristics of the S-100 protein, and later named calprotectin as a calcium binding protein with multiple protective functions.
Calprotectin is a heterodimeric complex consisting of S100A8 and S100A9 in the S100 calbindin family, a calcium-zinc binding protein from neutrophils and macrophages, detectable in serum, body fluids or feces, has been identified as a marker of IBD in inflammatory bowel disease, and elevated calprotectin (S100 A8/S100 A9) levels are currently detectable in populations of inflammation, tumor cells and cancer.
In the gynecological field, researches show that calprotectin has a certain relation with the occurrence of endometrial cancer related to inflammation, and plays an important role in the generation of inflammatory factors, the occurrence of tumors and the metastasis.
However, no relationship between ovarian lesions and calprotectin is found at present, and no relationship between ovarian lesions and calprotectin (FC) in feces is found.
Disclosure of Invention
The invention aims to provide application of a reagent for detecting the content of the calprotectin in preparing an ovarian lesion screening kit and a novel ovarian lesion screening kit.
The technical scheme of the invention comprises the following steps:
use of a reagent for detecting calprotectin in feces in the preparation of an ovarian lesion screening kit.
As for the aforementioned use, the reagent for detecting calprotectin in feces is: a reagent for immunohistochemical detection, a reagent for Western Blot detection, a reagent for colloidal gold detection or a reagent for ELISA detection.
The use as described above, the reagent further comprising a protein purification reagent.
The ovarian disease is premature ovarian failure, decreased ovarian reserve function, polycystic ovarian syndrome, accessory cystic space and/or cysts.
As with the aforementioned use, if the kit detects a higher content of calprotectin in the stool of a female subject than in a normal female, the risk of ovarian disease in the female subject is high.
A ovarian lesion screening kit, comprising a reagent for detecting calprotectin in feces.
As with the kit described above, the reagents for detecting calprotectin in feces are: a reagent for immunohistochemical detection, a reagent for Western Blot detection, a reagent for colloidal gold detection or a reagent for ELISA detection.
Such as the aforementioned kit, which further comprises a protein purification reagent.
The kit as described above, wherein the ovarian disease is premature ovarian failure, diminished ovarian reserve function, polycystic ovarian syndrome, accessory cystic space occupation, and/or bursa.
As with the kit described above, if the kit detects a higher calprotectin content in the feces of a female subject than that of a normal female, the risk of ovarian disease in the female subject is high.
According to the invention, the correlation between the content and ovarian lesion is obvious through detecting the content of the calprotectin in different groups of people, and the kit developed by the principle can be used for quickly and non-invasively screening the ovarian lesion, so that the application prospect is good.
Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.
The present invention will be described in further detail with reference to the following examples. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Drawings
FIG. 1: the proportion of the faecal calprotectin in patients with various ovarian diseases is more than 15 ug/g.
FIG. 2: the proportion of the calprotectin in patients with various ovarian diseases is more than or equal to 60 ug/g.
FIG. 3: counting distribution intervals of the content of the calprotectin in patients with various ovarian diseases.
FIG. 4: and (4) counting distribution intervals of the content of the calprotectin in the patients with ovarian lesions.
In the drawings, FC means calprotectin.
Detailed Description
Example 1 screening kits (ELISA) of the invention
1. Composition of
(1) Pre-coating a plate: ninety-six well plates coated with anti-human calprotectin rabbit IgG antibody on the inner wall and bottom of the well.
(2) Enzyme-labeled antibody: (30-fold concentration) HRP-labeled anti-human calprotectin rabbit IgG antibody.
(3) And (3) standard substance: calprotectin.
(4) Buffer PBS containing 1% BSA, 0.05% Tween 20.
(5) The color developing agent is TMB substrate solution.
(6) Stopping liquid: 1N sulfuric acid.
2. Sample preparation
(1) Collecting a sample by using a special sample sampling adhesive device, and discharging excrement in the center of the unfolded adhesive device, wherein the excrement cannot be stained with pollutants such as urine, blood, toilet water, toilet paper and the like;
(2) Inserting a sampling rod into the excrement sample, then putting the sampling rod back into an excrement sampling tube filled with sample diluent, screwing and shaking uniformly, and repeating the actions for 3 times;
(3) Sampling at a plurality of different points of the same stool sample each time, wherein the total sampling amount is about 50mg (similar to the size of a match head);
(4) Screwing the sampling tube and shaking uniformly for later use;
(5) If the patient with diarrhea absorbs the thin excrement by a disposable suction tube, about 100uL (3 drops) of the thin excrement is collected into an excrement sampling tube, the thin excrement is fully shaken up for standby, and the detection is carried out as soon as possible.
3. Use of
(1) Adding 0.1mL of serum sample (standard product) into the pre-coated plate hole, incubating for 30min at 37 ℃, pouring off liquid in the hole, beating for 3 times, and reducing liquid adhesion;
(2) The protein not bound to the pre-coated plate was washed with 0.15mL buffer and repeated 5 times;
(3) Adding 0.1mL of enzyme-labeled antibody, incubating for 30min at 37 ℃, pouring off the enzyme-labeled antibody, and adding 0.15mL of buffer solution for washing for 5 times;
(4) Adding 0.1mL of color developing agent, and incubating at 37 ℃ for 10min;
(5) Adding 0.05mL of stop solution;
(6) And (4) judging a result: the color depth is observed by naked eyes, and the deeper the color is, the stronger the positive degree is; or measuring the OD (450 nm).
The standard curve can be prepared by the steps of diluting the standard substance with gradient in advance, and the concentration of the sample is adjusted when the sample is formally detected so that the concentration falls in a linear interval (a curve of the concentration and the OD value).
The screening kit can also be prepared by the following method:
and (3) replacing the corresponding protein standard in any commercial protein detection kit with a calprotectin solution, and replacing the antibody with an anti-calprotectin antibody.
Example 2 relationship between ovarian lesions and the content of calprotectin (FC)
The inventor carried out fecal calprotectin detection (using calprotectin detection kit (colloidal gold method) of xiamen, zhengzhi biotechnology limited company) on partial infertility patients diagnosed by the outpatient clinic of the university of traditional Chinese medicine university, wherein 32 patients confirmed to be diagnosed with ovarian lesions through ultrasound and sex hormone examination (4 cases of Premature Ovarian Failure (POF), 6 cases of ovarian reserve function Decline (DOR), 16 cases of polycystic ovarian syndrome (PCOS), 4 cases of accessory cystic occupation and 2 cases of bursa of fabricius). And healthy adult women were monitored for calprotectin as a control.
The detection method comprises the following steps:
1. patient pre-test preparation
(1) For the first detection, a patient needs to collect a detection sample before taking medicine and clysis;
(2) The patient needs to be taken after stopping taking the medicine for at least 24 hours;
(3) The diet 24 hours before sampling is preferably similar to that of the ordinary diet, so that overeating or taking of excessive spicy and pungent foods is avoided, and drinking is forbidden;
(4) The patient can not stay up night before sampling (the sleeping time is guaranteed to be more than or equal to 6 hours);
(5) During menstruation, sampling is not suitable;
(6) If the condition allows the feces sample of the first defecation of the patient in the early morning to be collected as much as possible for detection;
(7) Patients who cannot be sampled according to the sampling requirements are not suitable for testing.
2. Sample collection and detection
(1) Collecting samples by using a special sample sampling adhesive device, discharging excrement in the center of the unfolded adhesive device, and paying attention to the fact that the excrement cannot be stained with pollutants such as urine, blood, toilet water, toilet paper and the like;
(2) Inserting a sampling rod into the excrement sample, then putting the sampling rod back into an excrement sampling tube filled with sample diluent, screwing and shaking uniformly, and repeating the actions for 3 times;
(3) Sampling at a plurality of different points of the same stool sample each time, wherein the total sampling amount is about 50mg (similar to the size of a match head);
(4) Screwing the sampling tube and shaking uniformly for later use;
(5) If a patient with diarrhea absorbs the thin excrement by using a disposable suction tube, collecting about 100uL (3 drops) of the thin excrement into an excrement sampling tube, fully shaking the thin excrement into a uniform state for standby, and detecting as soon as possible;
(6) Taking out the matched detection card from the aluminum foil bag, marking and horizontally placing the detection card on a horizontal workbench;
(7) Unscrewing a cap of the sampling pipe, discarding two drops of diluted samples, slowly and vertically dripping 100uL (3 drops) of bubble-free diluted samples at the center of a sample adding hole of a detection card, inserting the detection card into a calprotectin detector, and starting timing;
(8) The result is interpreted within 10-15min, and the test result is invalid after 15 min.
The results are as follows:
by comparing the positive rates of various ovarian lesions (as shown in figure 1 and figure 2), if FC > 15ug/g is taken as a positive predictive value, 4 POF patients with FC positive are detected, and the positive rate is 100%; 4 cases of FC-positive DOR patients with a positive rate of 66.7%; 12 PCOS patients with FC-positive had a 75% positive rate; FC-positive annex cystic occupancy patients in 3 cases showed 75% positive, and FC-positive chocolate capsular patients in 0 cases showed 0% positive. If FC is more than or equal to 60ug/g as a positive predicted value, the positive rate is 33.33 percent in 2 cases of FC-positive DOR patients; FC-positive PCOS patients 5 with a positive rate of 31%; FC-positive annex cystic occupancy of 1 patient with a positive rate of 25%; FC-positive POF and bursal patients have not been detected.
FC value distribution interval of ovarian lesion (fig. 3, fig. 4): FC values in patients with ovarian lesions are mainly concentrated in the 15-60ug/g interval (15, 46.875%). The FC positive minimum value of the POF patient is 17ug/g, and the maximum value is 57ug/g; the FC positive minimum value of the DOR patient is 24ug/g, and the maximum value is more than 1000ug/g; FC positive of PCOS patient has the lowest value of 34ug/g and the highest value of 432ug/g; the accessory cystic occupancy patient has a FC positive minimum of 50ug/g and a maximum of 138ug/g.
If the FC content is more than or equal to 15ug/g, the positive result is obtained. 40 healthy women are aged (31.272 +/-6.604), 28 calprotectin FC (FC < 15), 12 FC (FC > 15), the highest positive FC value of 56ug/g and the FC content (34.927 +/-9.134) ug/g of positive women are selected; 32 ovarian disease patients, 9 ovarian disease patients with age (32.955 +/-7.006) and FC <15, and 23 ovarian disease patients with FC > 15 have a positive rate of 71.8%; the FC content (218.677 +/-173.623) ug/g of positive persons has the highest positive value of more than 1000ug/g, and the difference of the positive values (15-1000 ug/g) of the two groups of FC has statistical significance (P is less than 0.05). Specifically, the following tables 1 and 2 show the results.
TABLE 1 ovarian lesion FC positive rate (FC content ≥ 15 ug/g)
Table 2 FC positive ovarian lesions in comparison to healthy women
From global considerations (including FC <15ug/g and FC ≧ 15 ug/g), both healthy women and patients with ovarian lesions will have FC means that are pulled low by the FC-negative (FC <15 ug/g) segment of the data. But the proportion of FC <15ug/g of healthy women is obviously larger than that of ovarian disease patients, the FC mean value of the healthy women is pulled lower in the FC negative part data, and the FC value difference of the healthy women and the ovarian disease patients is larger. It can be seen that FC values of healthy women and ovarian disease patients are very different from each other globally, and healthy women and women with ovarian disease patients can be distinguished by FC values.
This example shows that the FC content of patients with ovarian disorders is significantly higher than that of healthy women, and women with high FC content are at higher risk of suffering from ovarian disorders.
In conclusion, the ovarian lesion is related to calprotectin in feces, the kit disclosed by the invention can be used for rapidly screening the ovarian lesion by detecting calprotectin in a feces sample, judging the risk of the ovarian lesion of a target group is high or low, if the FC content is high, the risk is high, and if the FC content is low, the risk is low.
Claims (4)
1. Use of a reagent for detecting calprotectin in feces in the preparation of an ovarian lesion screening kit, characterized in that the ovarian lesion is premature ovarian failure, decreased ovarian reserve function, polycystic ovarian syndrome and/or accessory cystic space occupation.
2. The use of claim 1, wherein the agent for detecting calprotectin in faeces is: a reagent for immunohistochemical detection, a reagent for Western Blot detection, a reagent for colloidal gold detection or a reagent for ELISA detection.
3. Use according to claim 1, characterized in that: the reagents also include protein purification reagents.
4. Use according to any one of claims 1 to 3 wherein the risk of ovarian disease in a female subject is increased if the kit detects a higher calprotectin content in the faeces of a female subject than in a normal female.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910937671 | 2019-09-27 | ||
| CN2019109376713 | 2019-09-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112578125A CN112578125A (en) | 2021-03-30 |
| CN112578125B true CN112578125B (en) | 2022-10-25 |
Family
ID=75119652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011038492.5A Active CN112578125B (en) | 2019-09-27 | 2020-09-27 | Application of reagent for detecting content of calprotectin in preparation of ovarian lesion screening kit |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN112578125B (en) |
| WO (1) | WO2021057986A1 (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1724585A1 (en) * | 2005-05-21 | 2006-11-22 | ProteoSys AG | Annexin for cancer risk assessment |
| AU2010210312A1 (en) * | 2009-02-09 | 2011-08-04 | Patrys Limited | SAM-6 variants, target and methods of use |
| CN103797131A (en) * | 2011-06-16 | 2014-05-14 | 卡里斯生命科学卢森堡控股有限责任公司 | Biomarker compositions and methods |
| WO2018112460A1 (en) * | 2016-12-16 | 2018-06-21 | The Brigham And Women's Hospital, Inc. | System and method for protein corona sensor array for early detection of diseases |
| CA2963123A1 (en) * | 2017-03-31 | 2018-09-30 | Mark Trifiro | Poly-glutamine androgen receptor knock-in animal models, reagents and methods |
| CN111526883A (en) * | 2017-11-03 | 2020-08-11 | 自然阳光生产公司 | Methods and compositions for enhancing metabolic detoxification systems |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7659087B2 (en) * | 2004-07-23 | 2010-02-09 | Aspenbio Pharma, Inc. | Methods and devices for diagnosis of appendicitis |
| BRPI0513740A (en) * | 2004-07-23 | 2008-05-13 | Aspenbio Pharma Inc | Method and device for the diagnosis of appendicitis |
| US20120258477A1 (en) * | 2011-07-25 | 2012-10-11 | Northwestern University | Fecal neopterin concentration measurement as an indicator of disease activity in inflammatory bowel disease |
| CN102559598A (en) * | 2011-12-27 | 2012-07-11 | 陆华 | Preparation and detection method for heat shock apoptosis intracranial glioma cells |
| EP3882633A1 (en) * | 2012-02-09 | 2021-09-22 | MeMed Diagnostics Ltd. | Signatures and determinants for diagnosing infections and methods of use thereof |
| WO2013132347A2 (en) * | 2012-03-06 | 2013-09-12 | Calpro As | Improved elisa immunoassay for calprotectin |
| BR112015022597A2 (en) * | 2013-03-13 | 2017-10-24 | Cour Pharmaceuticals Dev Company | immunity modifying particles for the treatment of inflammation |
| CN103207274B (en) * | 2013-04-28 | 2015-02-25 | 成都中医药大学 | Screening kit for seventh chromosome abnormality diseases of fetus |
| EP3185881B1 (en) * | 2014-08-26 | 2022-03-09 | Betanien Hospital | Methods, agents and compositions for treatment of inflammatory conditions |
| US20180356405A1 (en) * | 2015-09-29 | 2018-12-13 | Essenlix Corp. | Method of Detecting an Analyte in a Sample |
| CN105181977A (en) * | 2015-11-05 | 2015-12-23 | 四川沃文特生物技术有限公司 | Kit for detecting calprotectin in excrement |
| CN105842459A (en) * | 2016-03-24 | 2016-08-10 | 泰州海路生物技术有限公司 | Immuno-chromatography kit for quickly and quantitatively detecting calprotectin in excrement |
| WO2017180909A1 (en) * | 2016-04-13 | 2017-10-19 | Nextgen Jane, Inc. | Sample collection and preservation devices, systems and methods |
| CN107085116A (en) * | 2017-05-16 | 2017-08-22 | 张子林 | It is a kind of to detect kit of calprotectin and preparation method thereof in human faecal mass sample |
| CN110221079B (en) * | 2019-06-20 | 2022-07-12 | 北京林业大学 | Application of fecal calprotectin and lactoferrin detection in diagnosis of inflammatory diseases of forest musk deer intestinal tract |
-
2020
- 2020-09-27 CN CN202011038492.5A patent/CN112578125B/en active Active
- 2020-09-27 WO PCT/CN2020/118200 patent/WO2021057986A1/en active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1724585A1 (en) * | 2005-05-21 | 2006-11-22 | ProteoSys AG | Annexin for cancer risk assessment |
| AU2010210312A1 (en) * | 2009-02-09 | 2011-08-04 | Patrys Limited | SAM-6 variants, target and methods of use |
| CN103797131A (en) * | 2011-06-16 | 2014-05-14 | 卡里斯生命科学卢森堡控股有限责任公司 | Biomarker compositions and methods |
| WO2018112460A1 (en) * | 2016-12-16 | 2018-06-21 | The Brigham And Women's Hospital, Inc. | System and method for protein corona sensor array for early detection of diseases |
| CA2963123A1 (en) * | 2017-03-31 | 2018-09-30 | Mark Trifiro | Poly-glutamine androgen receptor knock-in animal models, reagents and methods |
| CN111526883A (en) * | 2017-11-03 | 2020-08-11 | 自然阳光生产公司 | Methods and compositions for enhancing metabolic detoxification systems |
Non-Patent Citations (5)
| Title |
|---|
| "Research advances in the role of fecal calprotectin in intestinal development and diseases among children";Li Feng 等;《Chinese journal of contemporary pediatrics》;20141001;第16卷(第10期);第1064-1069页 * |
| "The role of calprotectin in obstetrics and gynecology";Ioannis D.Kostakis 等;《European Journal of Obstetrics & Gynecology and Reproductive Biology》;20100407;第151卷(第1期);第3-9页 * |
| "镉对去卵巢大鼠钙代谢的影响";杨学斌 等;《中国公共卫生》;20040108;第19卷(第1期);第23-25页 * |
| 肠道菌群失调在多囊卵巢综合征代谢异常中的作用;刘慧萍 等;《实用妇产科杂志》;20190415(第04期);第28-30页 * |
| 钙卫蛋白与肿瘤关系研究进展;张若旸 等;《肿瘤防治研究》;20160825;第43卷(第08期);第713-716页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112578125A (en) | 2021-03-30 |
| WO2021057986A1 (en) | 2021-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mischke et al. | Changes in C-reactive protein and haptoglobin in dogs with lymphatic neoplasia | |
| Rakhila et al. | Promotion of angiogenesis and proliferation cytokines patterns in peritoneal fluid from women with endometriosis | |
| Wells | The pathology of gestational trophoblastic disease: recent advances | |
| Esters et al. | Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn’s disease | |
| US7732148B2 (en) | Annexin A3 for prostate cancer diagnosis | |
| CN102625914B (en) | The method of detection carcinoma of urinary bladder or carcinoma of urinary bladder risk | |
| Limburg et al. | Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia | |
| Plata-Nazar et al. | Clinical usefulness of determining the concentration of neopterin | |
| Dima et al. | Clinical significance of serum and urinary interleukin-6 in systemic lupus erythematosus patients | |
| CN112578125B (en) | Application of reagent for detecting content of calprotectin in preparation of ovarian lesion screening kit | |
| CN112578122B (en) | Application of reagent for detecting content of calprotectin in preparation of teratospermia screening kit | |
| CN104865384A (en) | Renal failure rapid detection triple kit and preparation method and application thereof | |
| Holmes et al. | Fast facts: celiac disease | |
| CN112578123B (en) | Application of reagent for detecting content of calprotectin in preparation of uterine lesion screening kit | |
| US20120149043A1 (en) | Urinary biomarkers for cancer diagnosis | |
| CN112578124A (en) | Application of reagent for detecting content of calprotectin in preparation of fallopian tube lesion screening kit | |
| Shariff | Fundamentals of Surgical Pathology | |
| Nakamura et al. | Renal Tubular Function Modulates Urinary Levels of lnterleukin-6 | |
| Zyambo et al. | Reduced fractional absorption of zinc in children with environmental enteropathy in Zambia | |
| Fadare et al. | Epithelioid smooth muscle tumors of the uterus do not express CD1a: a potential immunohistochemical adjunct in their distinction from uterine perivascular epithelioid cell tumors | |
| De Smit et al. | AB0119 Rheumatoid arthritis (RA)-associated autoantibodies are present in the periodontal exudate of patients with and without ra | |
| JP2002544520A (en) | Method for predicting and / or diagnosing the risk of gastric cancer | |
| JP6192177B2 (en) | Use of S100A9 as a biomarker for inflammatory bowel disease | |
| Ekici et al. | Benign mixed epithelial and stromal tumor of the kidney | |
| Capellari et al. | Autoantibodies research in patients with endometriosis: A cross-sectional study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |